SAB BIO

About SAB BIO

SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing disease-modifying immunotherapies to delay the onset and progression of type 1 diabetes (T1D). Their mission is to change the lives of people impacted by T1D through unique therapies that address the underlying cause of the disease.

Products & Services

SAB-142:A disease-modifying immunotherapy aimed at delaying the onset and progression of type 1 diabetes by preserving beta cell function and addressing the over-reactive immune response that attacks insulin-producing cells.

Specialties

Immunotherapy Type 1 Diabetes (T1D) treatment Human anti-thymocyte immunoglobulin (hIgG)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 85000000 MR: - FA: approximately $85 million FAN: 85000000	D: 2026-03-19 FD: 2026-03-19	5 investors
2	RT: Private Placement T: - FT: Private Placement	A: 175000000 MR: - FA: 175 million FAN: 175000000	D: 2025-07-21 FD: 2025-07-21	11 investors
3	RT: Private Placement T: - FT: Private Placement	A: 67100000 MR: - FA: $67.1 Million FAN: 67100000	D: 2023-11-14 FD: 2023-11-14	6 investors
4	RT: Private Placement T: - FT: Private Placement	A: 130000000 MR: - FA: up to $130 million FAN: 130000000	D: 2023-10-02 FD: 2023-10-02	7 investors

Public Offering Latest

2026-03-19

$85.0M

5 investors (Pro only)

Private Placement 2025-07-21

$175.0M

Private Placement 2023-11-14

$67.1M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Katie Ellias

Director

S

Scott Giberson, RPh, MPH, D.Sc.

Director

C

Christine Hamilton, MBA

Chairperson of Compensation Committee

D

David Link, MBA

Chairperson of Nominating and Corporate Governance Committee

E

Erick Lucera, CFA

Chairperson of Audit Committee and Member of Compensation Committee

A

Andrew Moin

Board Member

View 33 more team members with Pro

Unlock Full Team Directory

Recent News

SAB BIO Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised